Allstar

Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an Anterior Myocardial Infarction and Ischemic Left Ventricular Dysfunction

Allstar [NCT01458405]

Description: The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.

Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells

Primary Investigator: Kereiakes

Drug/Device Information
Study of the safety and efficacy of intracoronary delivery of Allogeneic Cardiosphere-Derived Cells in patients with a myocardial infarction and ischemic left ventricular dysfunction
CAP-1002 CDCs are grown from donated human myocardial tissue
Randomized 2:1 CAP-1002 to Placebo delivered via an intracoronary infusion
Capricor, Inc.